This study will evaluate the safety, tolerability and efficacy of AXR-270 Cream in treating posterior blepharitis associated with Meibomian Gland Disease (MGD)
AXR201901 is a multicenter, randomized, double-masked, vehicle-controlled study of AXR-270 cream and AXR-270 vehicle in subjects with signs and symptoms of posterior blepharitis associated with meibomian gland dysfunction
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
QUADRUPLE
Enrollment
129
AXR-270 Topical Eyelid Cream
AXR-270 Topical Eyelid Cream
AXR-270 Topical Eyelid Cream Vehicle
AxeroVision, Inc.
Carlsbad, California, United States
Adverse Events
Incidence of treatment emergent ocular and systemic adverse events (TEAE)
Time frame: 22 Days
Total Meibomian Gland Dysfunction Score
Change from Baseline in total MGD score (Study Eyelid): The total MGD score is the sum of secretion of 5 central glands on the upper and lower eyelids. Each gland orifice was scored from 0-3. The total score range was from 0-15 per eyelid. The numbers reported are for the Study Eyelid of each subject (=eyelid with higher sum score of the Total MGD score and Vascularity of Eyelid Margin score at baseline). Greater negative scores indicate a better outcome. Scores: 0 = clear/slightly yellow; 1 = opaque/yellow, whitish, particulate; 2 = paste; 3 = none/occluded.
Time frame: 22 Days
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.